Display options
Share it on
Full text links
Nature Publishing Group Free PMC Article

Br J Cancer. 1993 Jan;67(1):128-33. doi: 10.1038/bjc.1993.22.

Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation.

British journal of cancer

C Taylor, K Patel, T Jones, F Kiely, B L De Stavola, D Sheer

Affiliations

  1. Human Cytogenetics Laboratory, Imperial Cancer Research Fund, London, UK.

PMID: 8381297 PMCID: PMC1968231 DOI: 10.1038/bjc.1993.22
Free PMC Article

Abstract

Fluorescence in situ hybridisation (FISH) has been used increasingly for gene mapping and ordering probes on interphase and metaphase preparations. The association of consistent chromosomal aberrations with certain malignancies allows the possibility of using interphase cytogenetics as a diagnostic tool. In small round cell tumours of children accurate diagnosis may be difficult using existing methods. We have therefore evaluated the diagnostic potential of this technique when applied to the characteristic t(11;22) found in Ewing's sarcoma and peripheral neuroectodermal tumour (ES and PNET). Interphase nuclei were prepared from normal human foreskin fibroblasts (HFF), two Ewing's sarcoma cell lines and several fresh tumour biopsies. DNA probes each side of the breakpoint at 22q12 were labelled with biotin and digoxygenin, hybridised to chromosomes in interphase and detected in different colours. Measurements between pairs of signals arising from each copy of chromosome 22 were taken and statistical analysis performed. There was a highly significant difference (P < 0.0001) between the two populations of measurements obtained (from nuclei with and without the t(11;22)). Studying four tumours and one further ES line (blind) it was found that median values from 30 nuclei could correctly identify which samples contained the t(11;22). This application of interphase cytogenetics contributes a reliable, accurate and conceptually simple diagnostic test for ES and PNET. It may now be applied to other tumours with characteristic translocations, amplifications or deletions when suitable probes are available. This approach is likely to become a routine in clinical diagnosis.

Cited by

References

  1. N Engl J Med. 1984 Aug 30;311(9):584-5 - PubMed
  2. Genes Chromosomes Cancer. 1991 Sep;3(5):382-9 - PubMed
  3. Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 - PubMed
  4. Hum Genet. 1987 Dec;77(4):366-70 - PubMed
  5. Br J Cancer. 1988 Jan;57(1):121-6 - PubMed
  6. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2623-7 - PubMed
  7. J Clin Oncol. 1988 Oct;6(10):1569-75 - PubMed
  8. Genomics. 1989 Nov;5(4):710-7 - PubMed
  9. Cytogenet Cell Genet. 1989;52(1-2):19-22 - PubMed
  10. Science. 1990 Aug 24;249(4971):928-32 - PubMed
  11. Science. 1990 Oct 26;250(4980):559-62 - PubMed
  12. Cancer Genet Cytogenet. 1991 Jan;51(1):13-22 - PubMed
  13. N Engl J Med. 1991 Feb 14;324(7):436-42 - PubMed
  14. Genes Chromosomes Cancer. 1989 Nov;1(2):159-66 - PubMed
  15. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):887-91 - PubMed
  16. Genet Anal Tech Appl. 1991 Apr;8(2):67-74 - PubMed
  17. Cancer Genet Cytogenet. 1991 Jul 1;54(1):1-10 - PubMed
  18. Mayo Clin Proc. 1985 Oct;60(10):675-89 - PubMed

MeSH terms

Publication Types

Grant support

LinkOut - more resources